Intrinsic Imaging Awarded International Phase III Clinical Trial for Cystic Fibrosis

Bolton, MA, San Antonio, TX (PRWEB) July 18, 2012 — Intrinsic Imaging, an ISO 9001:2008 certified and GAMP 5 medical imaging core lab specializing in providing imaging core lab services for clinical trials, announces today that it was recently awarded an important Phase III clinical trial for the study of Cystic Fibrosis (CF).

This international multicenter clinical trial studies an investigational new drug targeted at treating CF. During this trial, Intrinsic Imaging will evaluate Cystic Fibrosis lung pathophysiology to gain insights into the treatment's effect on major manifestations of CF.

"We are honored to have been selected to provide central imaging core lab services for this important Phase III trial for Cystic Fibrosis," said Todd A. Joron, BSc. MBA, President and Chief Operating Officer, Intrinsic Imaging. "We look forward to contributing our imaging expertise in support of treating this systemic and complex disease."

Intrinsic Imaging's team of more than sixty board-certified diagnostic radiologists has subspecialization in all therapeutic areas. The team dedicated to this trial consists of 12 fellowship-trained board-certified radiologists with deep therapeutic expertise in thoracic disease including Cystic Fibrosis, Chronic Obstructive Pulmonary Disease, Emphysema, Interstitial Lung Disease (ILD) and the full scope of pulmonary tumors.

"Intrinsic Imaging's capabilities in evaluating Cystic Fibrosis lung pathophysiology include, but are not limited to, the interpretation and scoring of bronchiectasis, mucous plugging, peribronchial thickening, parenchymal opacities and hyperinflation, among others," said Dr. Amit Mehta, Vice-President, Radiology at Intrinsic Imaging. "Our team has specialized training and expertise in adult and pediatric pulmonary disease and are readily able to provide clinical image management and radiological review for Cystic Fibrosis as well as other pulmonary related clinical trials."

Cystic fibrosis is a rare, life threatening genetic disease marked by the production of abnormally viscous mucus by the affected glands, usually resulting in impaired pancreatic function and chronic respiratory infections. Over time, inflammation and infection cause injury and structural changes to the lungs, leading to a variety of symptoms and in later stages, changes in the architecture of the lung further exacerbate difficulties in breathing.